Supplementary Tables 2 - 6 from Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases

Authors:
  • PPPaul K. Paik
    Paul K. Paik
  • RSRonglai Shen
    Ronglai Shen
  • HWHelen Won
    Helen Won
  • NRNatasha Rekhtman
    Natasha Rekhtman
  • LWLu Wang
    Lu Wang
  • CSCamelia S. Sima
    Camelia S. Sima
  • AAArshi Arora
    Arshi Arora
  • VSVenkatraman Seshan
    Venkatraman Seshan
  • MLMarc Ladanyi
    Marc Ladanyi
  • MBMichael F. Berger
    Michael F. Berger
  • MKMark G. Kris
    Mark G. Kris

Abstract
Supplementary Table 2. Frequency of selected genes in SQ-MAP vs. TCGA. Supplementary Table 3. Clinical characteristics of patients with resected brain metastases. Supplementary Table 4. Genes exhibiting clonal evolution from primary lung tumors and matched brain metastases. Data from PP1 and PP4 are shown. Supplementary Table 5. List of 279 oncogenes and tumor suppressors covered by the Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) assay. Supplementary Table 6. Computational estimates of tumor purity (fractional) from whole-exome sequencing data for the paired lung primary and brain metastasis tumor samples compared to pathological evaluation of tumor purity in the same samples.